On April 6, 2023 at 10:11:23 ET an unusually large
$17.57K block of Call contracts in Seelos Therapeutics
(SEEL) was sold,
with a strike price of $1.00 / share, expiring in 288 days (on January 19, 2024).
Fintel tracks all large options trades, and the premium spent on this trade was 1.25 sigmas above the mean, placing it in the 94.11 percentile of all recent large trades made in SEEL options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 620.44% Upside
As of April 6, 2023,
the average one-year price target for Seelos Therapeutics is $5.36.
The forecasts range from a low of $3.03 to a high of $11.55.
The average price target represents an increase of 620.44% from its latest reported closing price of $0.74.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Seelos Therapeutics
is $0MM, a decrease of �%.
The projected annual non-GAAP EPS
is -$0.50.
What is the Fund Sentiment?
There are 101 funds or institutions reporting positions in Seelos Therapeutics.
This is a decrease
of
19
owner(s) or 15.83% in the last quarter.
Average portfolio weight of all funds dedicated to SEEL is 0.05%,
a decrease
of 55.10%.
Total shares owned by institutions decreased
in the last three months by 16.33% to 24,271K shares.
The put/call ratio of SEEL is 0.09, indicating a
bullish
outlook.
What are Large Shareholders Doing?
Gendell Jeffrey L
holds 4,909K shares
representing 4.05% ownership of the company.
No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares
holds 3,357K shares
representing 2.77% ownership of the company.
No change in the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares
holds 1,478K shares
representing 1.22% ownership of the company.
In it’s prior filing, the firm reported owning 1,476K shares, representing
an increase
of 0.16%.
The firm
decreased
its portfolio allocation in SEEL by 36.37% over the last quarter.
Group One Trading
holds 1,287K shares
representing 1.06% ownership of the company.
In it’s prior filing, the firm reported owning 2,162K shares, representing
a decrease
of 67.96%.
The firm
decreased
its portfolio allocation in SEEL by 53.55% over the last quarter.
Mirae Asset Global Investments Co.
holds 1,232K shares
representing 1.02% ownership of the company.
In it’s prior filing, the firm reported owning 1,761K shares, representing
a decrease
of 42.85%.
The firm
decreased
its portfolio allocation in SEEL by 75.60% over the last quarter.
Seelos Therapeutics Background Information
(This description is provided by the company.)
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
